Stockscreener 앱 받기
0.3987
0.10%
0.0004
시간 외 거래:
.41
0.0113
+2.83%
Applied Therapeutics Inc 주식(APLT)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Applied Therapeutics Inc (NASDAQ:APLT)’s 12-Month Price Target Is Now Set At 5. - Marketing Sentinel
APLT stock touches 52-week low at $0.3 amid sharp annual decline By Investing.com - Investing.com South Africa
APLT stock touches 52-week low at $0.3 amid sharp annual decline - Investing.com
Applied Therapeutics Reports 2024 Financial Results and Leadership Changes - TipRanks
Applied Therapeutics, Inc. SEC 10-K Report - TradingView
Applied Therapeutics (APLT) Reports Lower Revenue But Reinforces Strategic Focus | APLT Stock News - GuruFocus
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Fi - GuruFocus
Applied Therapeutics earnings beat by $0.71, revenue fell short of estimates - Investing.com Canada
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results - The Manila Times
Applied Therapeutics Strengthens Balance Sheet: $79.4M Cash Position Powers Drug Development Push - Stock Titan
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results | APLT Stock News - GuruFocus
Norges Bank Acquires New Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics LawsuitAPLT - ACCESS Newswire
APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Applied Therapeutics, Inc.(APLT) should contact The Gross Law Firm about pending Class ActionAPLT - MarketScreener
APLT stock touches 52-week low at $0.42 amid sharp annual decline - Investing.com Australia
Investors Who Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky About Pending Class ActionAPLT - ACCESS Newswire
APLT stock touches 52-week low at $0.42 amid sharp annual decline By Investing.com - Investing.com South Africa
Applied Therapeutics, Inc. (APLT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Class Action Filed Against Applied Therapeutics, Inc. (APLT) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
APLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Charles Schwab Investment Management Inc. Has $600,000 Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics Delays Yearly Report Filing - TipRanks
Applied Therapeutics files Form 12b-25 with SEC - TipRanks
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission - GlobeNewswire
Applied Therapeutics Requests SEC Extension: What This Means for 2024 Financial Results - Stock Titan
146,900 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Swiss National Bank - Defense World
Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Lost Money on Applied Therapeutics, Inc.(APLT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Applied Therapeutics appoints new Chief Regulatory Officer By Investing.com - Investing.com South Africa
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer - citybiz
APLT DEADLINE ALERT: Applied Therapeutics Investors have until February 18 before Expiration of the Class Action DeadlineContact BFA Law if You Lost Money - Louisiana First News
Applied Therapeutics Names Todd Baumgartner As Chief Regulatory Officer - Nasdaq
Applied Therapeutics appoints new Chief Regulatory Officer - Investing.com
Applied Therapeutics Strengthens Drug Approval Push With 12-Time FDA Success Veteran - Stock Titan
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) Price Target at $6.10 - MarketBeat
Applied Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire
Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
0.24%
36.06%
자본화:
|
볼륨(24시간):